Dr. Reddy's Laboratories Financial Statements (RDY)
|
|
|
|
Report date
|
|
|
13.06.2023 |
31.03.2024 |
12.06.2024 |
06.06.2025 |
31.03.2026 |
|
12.05.2026 |
|
Currency
|
|
|
INR |
INR |
INR |
INR |
INR |
|
INR |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, ₹ |
? |
|
245 879 000 000 |
279 164 000 000 |
279 164 000 000 |
325 535 000 000 |
353 471 642 000 |
|
337 102 392 460 |
|
Operating Income, ₹ |
|
|
57 144 000 000 |
66 208 000 000 |
67 729 000 000 |
71 843 000 000 |
48 867 731 000 |
|
49 699 250 095 |
|
EBITDA, ₹ |
? |
|
74 431 000 000 |
81 049 000 000 |
88 422 000 000 |
96 671 000 000 |
70 549 544 000 |
|
74 646 003 069 |
|
Net profit, ₹ |
? |
|
45 067 000 000 |
55 684 000 000 |
55 684 000 000 |
56 544 000 000 |
45 087 145 000 |
|
42 883 243 739 |
|
|
OCF, ₹ |
? |
|
58 875 000 000 |
45 433 000 000 |
45 433 000 000 |
46 428 000 000 |
56 645 658 000 |
|
56 547 807 000 |
|
CAPEX, ₹ |
? |
|
18 866 000 000 |
16 403 000 000 |
27 435 000 000 |
34 398 000 000 |
24 543 821 000 |
|
32 290 826 000 |
|
FCF, ₹ |
? |
|
40 009 000 000 |
29 030 000 000 |
17 998 000 000 |
12 030 000 000 |
32 101 837 000 |
|
24 256 982 000 |
|
Dividend payout, ₹
|
|
|
4 979 000 000 |
6 648 000 000 |
6 648 000 000 |
6 662 000 000 |
7 006 658 000 |
|
6 700 138 000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
11.0% |
11.9% |
11.9% |
11.8% |
15.5% |
|
15.6% |
|
|
OPEX, ₹ |
|
|
82 199 000 000 |
95 731 000 000 |
95 878 000 000 |
118 585 000 000 |
137 651 001 000 |
|
128 088 924 308 |
|
Cost of production, ₹ |
|
|
106 536 000 000 |
115 557 000 000 |
115 557 000 000 |
135 107 000 000 |
166 952 910 000 |
|
159 314 217 963 |
|
R&D, ₹ |
|
|
19 381 000 000 |
22 873 000 000 |
22 873 000 000 |
27 380 000 000 |
25 314 038 000 |
|
24 142 994 871 |
|
Interest expenses, ₹ |
|
|
1 428 000 000 |
0.000 |
1 711 000 000 |
2 829 000 000 |
3 933 156 000 |
|
3 762 289 025 |
|
|
Assets, ₹ |
|
|
321 854 000 000 |
387 518 000 000 |
387 518 000 000 |
492 989 000 000 |
567 876 508 000 |
|
567 876 508 000 |
|
Net Assets, ₹ |
? |
|
230 991 000 000 |
280 550 000 000 |
280 550 000 000 |
333 388 000 000 |
369 598 167 000 |
|
369 598 167 000 |
|
Debt, ₹ |
|
|
13 472 000 000 |
20 020 000 000 |
20 020 000 000 |
46 766 000 000 |
75 809 856 000 |
|
75 809 856 000 |
|
Cash, ₹ |
|
|
61 797 000 000 |
81 470 000 000 |
81 470 000 000 |
57 908 000 000 |
86 075 519 000 |
|
86 075 519 000 |
|
Net debt, ₹ |
|
|
-48 325 000 000 |
-61 450 000 000 |
-61 450 000 000 |
-11 142 000 000 |
-10 265 663 000 |
|
-10 265 663 000 |
|
|
Ordinary share price, rub |
|
|
11.4 |
73.4 |
14.7 |
13.2 |
13.9 |
|
13.6 |
|
Number of ordinary shares, mln |
|
|
830 174 450 |
166 708 580 |
833 542 900 |
833 314 000 |
832 405 000 |
|
834 805 000 |
|
|
Market cap, ₹ |
|
|
9 455 686 986 |
12 228 074 343 |
12 228 074 343 |
10 991 411 660 |
11 528 809 250 |
|
11 361 696 050 |
|
EV, ₹ |
? |
|
-38 869 313 015 |
-49 221 925 657 |
-49 221 925 657 |
-150 588 340 |
1 263 146 250 |
|
1 096 033 050 |
|
Book value, ₹ |
|
|
195 897 000 000 |
239 346 000 000 |
239 346 000 000 |
224 775 000 000 |
253 981 299 000 |
|
253 981 299 000 |
|
|
EPS, rub |
? |
|
54.3 |
334.0 |
66.8 |
67.9 |
54.2 |
|
51.4 |
|
FCF/share, rub |
|
|
48.2 |
174.1 |
21.6 |
14.4 |
38.6 |
|
29.1 |
|
BV/share, rub |
|
|
236.0 |
1 436 |
287.1 |
269.7 |
305.1 |
|
304.2 |
|
|
EBITDA margin, % |
? |
|
30.3% |
29.0% |
31.7% |
29.7% |
20.0% |
|
22.1% |
|
Net margin, % |
? |
|
18.3% |
19.9% |
19.9% |
17.4% |
12.8% |
|
12.7% |
|
FCF yield, % |
? |
|
423.1% |
237.4% |
147.2% |
109.4% |
278.4% |
|
213.5% |
|
ROE, % |
? |
|
19.5% |
19.8% |
19.8% |
17.0% |
12.2% |
|
11.6% |
|
ROA, % |
? |
|
14.0% |
14.4% |
14.4% |
11.5% |
7.94% |
|
7.55% |
|
|
P/E |
? |
|
0.21 |
0.22 |
0.22 |
0.19 |
0.26 |
|
0.26 |
|
P/FCF |
|
|
0.24 |
0.42 |
0.68 |
0.91 |
0.36 |
|
0.47 |
|
P/S |
? |
|
0.04 |
0.04 |
0.04 |
0.03 |
0.03 |
|
0.03 |
|
P/BV |
? |
|
0.05 |
0.05 |
0.05 |
0.05 |
0.05 |
|
0.04 |
|
EV/EBITDA |
? |
|
-0.52 |
-0.61 |
-0.56 |
0.00 |
0.02 |
|
0.01 |
|
Debt/EBITDA |
|
|
-0.65 |
-0.76 |
-0.69 |
-0.12 |
-0.15 |
|
-0.14 |
|
|
R&D/CAPEX, % |
|
|
102.7% |
139.4% |
83.4% |
79.6% |
103.1% |
|
74.8% |
|
|
CAPEX/Revenue, % |
|
|
7.67% |
5.88% |
9.83% |
10.6% |
6.94% |
|
9.58% |
|
| Dr. Reddy's Laboratories shareholders |
